IRIS Accounts Production v25.1.3.33 03254007 Board of Directors 1.4.23 29.9.24 29.9.24 25.6.25 0 0 false true false false true false Auditors Opinion Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh032540072023-03-31032540072024-09-29032540072023-04-012024-09-29032540072022-03-31032540072022-04-012023-03-31032540072023-03-3103254007ns15:EnglandWales2023-04-012024-09-2903254007ns14:PoundSterling2023-04-012024-09-2903254007ns10:Director12023-04-012024-09-2903254007ns10:PrivateLimitedCompanyLtd2023-04-012024-09-2903254007ns10:SmallEntities2023-04-012024-09-2903254007ns10:Audited2023-04-012024-09-2903254007ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-09-2903254007ns10:SmallCompaniesRegimeForAccounts2023-04-012024-09-2903254007ns10:FullAccounts2023-04-012024-09-2903254007ns10:OrdinaryShareClass12023-04-012024-09-2903254007ns10:Director22023-04-012024-09-2903254007ns10:RegisteredOffice2023-04-012024-09-2903254007ns5:CurrentFinancialInstruments2024-09-2903254007ns5:CurrentFinancialInstruments2023-03-3103254007ns5:ShareCapital2024-09-2903254007ns5:ShareCapital2023-03-3103254007ns5:RetainedEarningsAccumulatedLosses2024-09-2903254007ns5:RetainedEarningsAccumulatedLosses2023-03-3103254007ns5:WithinOneYearns5:CurrentFinancialInstruments2024-09-2903254007ns5:WithinOneYearns5:CurrentFinancialInstruments2023-03-3103254007ns10:OrdinaryShareClass12024-09-29
REGISTERED NUMBER: 03254007 (England and Wales)




FINANCIAL STATEMENTS

FOR THE PERIOD

1 APRIL 2023 TO 29 SEPTEMBER 2024

FOR

MANX PHARMA LTD

MANX PHARMA LTD (REGISTERED NUMBER: 03254007)






CONTENTS OF THE FINANCIAL STATEMENTS
for the period 1 April 2023 to 29 September 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


MANX PHARMA LTD

COMPANY INFORMATION
for the period 1 April 2023 to 29 September 2024







DIRECTORS: Mrs S E Taylor
L D Taylor





REGISTERED OFFICE: Unit 2
Bosworth Avenue
Tournament Fields
Warwick
Warwickshire
CV34 6UQ





REGISTERED NUMBER: 03254007 (England and Wales)





AUDITORS: Luckmans Duckett Parker Limited
Chartered Accountants
Statutory Auditors
1110 Elliott Court
Herald Avenue
Coventry Business Park
Coventry
West Midlands
CV5 6UB

MANX PHARMA LTD (REGISTERED NUMBER: 03254007)

BALANCE SHEET
29 September 2024

2024 2023
Notes £    £   
CURRENT ASSETS
Debtors 4 105,227 101,364

CREDITORS
Amounts falling due within one year 5 438,743 434,894
NET CURRENT LIABILITIES (333,516 ) (333,530 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(333,516

)

(333,530

)

CAPITAL AND RESERVES
Called up share capital 6 100,000 100,000
Retained earnings (433,516 ) (433,530 )
SHAREHOLDERS' FUNDS (333,516 ) (333,530 )

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 25 June 2025 and were signed on its behalf by:





L D Taylor - Director


MANX PHARMA LTD (REGISTERED NUMBER: 03254007)

NOTES TO THE FINANCIAL STATEMENTS
for the period 1 April 2023 to 29 September 2024

1. STATUTORY INFORMATION

Manx Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The members' attention is drawn to the insolvent position of the balance sheet. The company will continue to trade with the support of the directors.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was NIL (2023 - NIL).

MANX PHARMA LTD (REGISTERED NUMBER: 03254007)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the period 1 April 2023 to 29 September 2024

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Amounts owed by group undertakings 103,106 101,364
Other debtors 103 -
Prepayments 2,018 -
105,227 101,364

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 4,036 187
Amounts owed to group undertakings 434,707 434,707
438,743 434,894

6. CALLED UP SHARE CAPITAL

Allotted and issued:
Number: Class: Nominal 2024 2023
value: £    £   
100,000 Ordinary shares £1 100,000 100,000

7. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Mark Spafford FCA FCCA (Senior Statutory Auditor)
for and on behalf of Luckmans Duckett Parker Limited

8. PARENT COMPANY

Manx Pharma Limited is a wholly owned subsidiary of Manx (Holdings) Limited, a company registered in England and Wales.